Thymidylate synthase expression in stage II and III colon cancer: A retrospective review

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 6, 2001, Pages 597-602

  Tomiak, Anna ^a,e   Vincent, Mark ^a   Earle, Craig C ^b   Johnston, Patrick G ^c   Kocha, Walter ^a   Taylor, Mariann ^a   Maroun, Jean ^d   Eidus, Leslie ^d   Whiston, Frances ^a   Stitt, Larry ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e Cancer Centre of South Eastern Ontario   (Canada)

Author keywords

Colon cancer; Predictive factor; Prognostic factor; Thymidylate synthase

Indexed keywords

FLUOROURACIL; MONOCLONAL ANTIBODY; THYMIDYLATE SYNTHASE;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COLON CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; REVIEW; STAINING; SURVIVAL RATE;

EID: 0035209477     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200112000-00014     Document Type: Review

References (32)

1. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report
2. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
3. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
4. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04
5. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089
6. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B and Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
7. Adjuvant therapy for stage II colon cancer after complete resection
8. Event free and overall survival is increased by FUFA in resected B colon cancer: A pooled analysis of five randomized trials (RCTS)
9. Microsatellite instability is a strong molecular predictive marker for sensitivity to adjuvant chemotherapy in Duke's C colorectal carcinoma
10. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
11. Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients
12. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protractedinfusion fluorouracil and weekly leucovorin
13. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial
14. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
15. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil
16. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
17. Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer
18. Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival
19. p53 and thymidylate synthase expression in untreated stage colon cancer: Associations with recurrence, survival, and site
20. Limited prognostic importance of immunohistochemical parameters (IHP) [thymidylate synthase (TS), KI-67, and P53] in 465 patients (pts) with Dukes' B2 and C colon cancer enrolled on North Central Cancer Treatment Group (NCCTG) trials
21. Thymidylate synthase (TS) and p53 expression predict for early event free survival (EFS) but not adjuvant chemotherapy efficacy in patients with colonic carcinoma (CC)
22. p53, p21 and thymidylate synthase (TS) protein expression: Associations with recurrence in stage II and III rectal cancer
23. Thymidylate synthase expression as a predictor for response to 5-fluorouracil-based therapy and survival for patients (pts) with resected colon or advanced colorectal cancer. An ECOG study
24. Prognostic role of thymidylate synthase (TS). p53, p21, KI67 and BCL-2 for patients (PTS) with colorectal cancer (CA) treated with surgery alone (SA) or with adjuvant 5-fluorouracil (5FU) and levamisole (LEV)
25. Thymidylate synthase expression predict prognosis of curatively resected colorectal carcinoma patients registered in an adjuvant immunochemotherapy clinical trial
26. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance
27. The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer
28. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue
29. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
30. Immunohistochemical determination of thymidylate synthase in colorectal cancer - Methodological studies
31. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers